NASDAQ$FATE
Fate Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Fate Therapeutics reported Q4 2023 financial results and business updates, highlighting progress in iPSC product platform and clinical programs.
Fate Therapeutics reported $1.7 million in revenue for Q4 2023, primarily from preclinical development activities under its collaboration with Ono. The company's cash, cash equivalents, and investments totaled $316.2 million as of December 31, 2023. Clinical development is ongoing across several iPSC-derived cellular immunotherapy programs.
- CIRM awarded a $7.9 million grant to support the Phase 1 autoimmunity study of FT819 for systemic lupus erythematosus.
- The first patient was treated in the Phase 1 study of FT522, an ADR-armed, CD19-targeted CAR NK cell program.
- A Phase 1 study of FT825 / ONO-8250 CAR T-cell program for solid tumors was initiated, incorporating seven synthetic controls.
- The company had $316.2 million in cash, cash equivalents, and investments as of December 31, 2023.
Headline financials
Revenue & EPS history
Fate Therapeutics · Revenue · Quarterly
$1.68M
Revenue by segment
Fate Therapeutics · $1.9M total across 1 segment · Q3 2023
- Collaboration Revenue$1.9M-87.3%100.0%
Forward guidance
Fate Therapeutics is focused on advancing its iPSC product platform in oncology and autoimmunity, with several clinical trials ongoing and initial clinical data expected in 2024.
Tailwinds
- Strong momentum across the iPSC product platform.
- Award of a grant by CIRM to support Phase 1 clinical investigation of FT819 in systemic lupus erythematosus.
- Treatment of the first patient with FT522, incorporating Alloimmune Defense Receptor technology.
- Initiation of the Phase 1 study of FT825 / ONO-8250 CAR T-cell program in solid tumors.
- Well positioned to generate initial clinical data across off-the-shelf programs during 2024.
Headwinds
- The company’s research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval.
- Results observed in prior studies of the company’s product candidates, including preclinical studies and clinical trials, may not be observed in ongoing or future studies involving these product candidates.
- There may be a delay or difficulties in the manufacturing of the company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials.
- The company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons.
- Its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+0.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+0.1%
Avg return
30 days after
44%
20 / 45 earnings
Positive
+19.0%
Q2 2016
Best reaction
-15.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | -22.8% | -8.5% | |
| Q4 2025 | +6.1% | -7.4% | -20.9% | |
| Q3 2025 | -2.1% | +6.1% | +16.2% | |
| Q1 2025 | -3.7% | +22.0% | +27.0% | |
| Q4 2024 | -1.6% | +2.2% | +20.7% | |
| Q3 2024 | -15.2% | -21.1% | -24.6% | |
| Q2 2024 | -1.8% | +2.1% | +12.3% | |
| Q1 2024 | +10.3% | +14.1% | -0.5% | |
| Q4 2023 | +7.2% | +11.2% | +5.5% | |
| Q3 2023 | -7.8% | -13.9% | -3.0% | |
| Q2 2023 | -4.2% | -13.0% | -30.4% | |
| Q1 2023 | +4.2% | -7.9% | -11.3% | |
| Q4 2022 | +1.3% | +1.7% | -11.8% | |
| Q3 2022 | -1.0% | -2.1% | +4.3% | |
| Q2 2022 | +6.3% | +11.5% | -12.8% | |
| Q1 2022 | -5.5% | -22.3% | -17.8% | |
| Q4 2021 | -1.5% | -7.0% | +14.1% | |
| Q3 2021 | +1.7% | +1.1% | -20.5% | |
| Q2 2021 | +14.8% | +15.0% | -12.3% | |
| Q1 2021 | -4.0% | -5.0% | -8.7% | |
| Q4 2020 | -9.6% | +1.2% | -24.4% | |
| Q3 2020 | -3.1% | +5.6% | +22.0% | |
| Q2 2020 | +2.5% | +10.4% | -4.6% | |
| Q1 2020 | -0.3% | -1.4% | +14.4% | |
| Q4 2019 | -3.3% | +0.9% | -30.8% | |
| Q3 2019 | -12.5% | -4.6% | -11.3% | |
| Q2 2019 | -3.8% | -2.9% | -6.0% | |
| Q1 2019 | -7.8% | -2.6% | -1.1% | |
| Q4 2018 | -3.1% | -0.1% | +12.0% | |
| Q3 2018 | +18.4% | +16.5% | +23.3% | |
| Q2 2018 | +15.6% | +17.6% | +28.6% | |
| Q1 2018 | -14.0% | -10.4% | +8.7% | |
| Q4 2017 | -1.6% | -0.8% | -20.8% | |
| Q3 2017 | -1.0% | +4.0% | -8.0% | |
| Q2 2017 | +6.7% | -3.4% | +44.6% | |
| Q1 2017 | +1.2% | -1.0% | -24.7% | |
| Q4 2016 | +5.5% | -3.4% | -10.4% | |
| Q3 2016 | +10.8% | +50.3% | +53.3% | |
| Q2 2016 | +19.0% | +21.3% | +20.9% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | +15.9% | — | — | |
| Q2 2015 | -5.1% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2014 | +3.9% | — | — | |
| Q3 2013 | +1.9% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro